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Abstract
Dentin sialophosphoprotein (DSPP) is pro-
teolytically processed into an NH2-terminal
fragment called dentin sialoprotein (DSP) and
a COOH-terminal fragment known as dentin
phosphoprotein (DPP). These two fragments
are believed to perform distinct roles in forma-
tion of bone and dentin. To investigate the
functions of DPP in skeletal development, we
generated transgenic mice to overexpress
hemagglutinin (HA)-tagged DPP under the
control of a 3.6 kb type I collagen (Col1a1) pro-
moter (designated as Col1a1-HA-DPP). The
Col1a1-HA-DPP transgenic mice were signifi-
cantly smaller by weight, had smaller skeletons
and shorter long bones than their wild type lit-
termates, as demonstrated by X-ray radiogra-
phy. They displayed reduced trabecular bone
formation and narrower zones of proliferative
and hypertrophic chondrocytes in the growth
plates of the long bones. Histological analyses
showed that the transgenic mice had reduced
cell proliferation in the proliferating zone, but
lacked obvious defects in the chondrocyte dif-
ferentiation. In addition, the transgenic mice
with a high level of transgene expression
developed spontaneous long bone fractures. In
conclusion, overexpressing DPP inhibited
skeletal development, suggesting that the bal-
anced actions between the NH2- and COOH-
terminal fragments of DSPP may be required
for normal skeletal development. 
Introduction
Discovered by cDNA cloning using a mouse
odontoblast cDNA library,1 the dentin
sialophosphoprotein (DSPP) gene is located
on human chromosome 4q21 and encodes the
most prominent non-collagenous protein
(NCP) in the dentin matrix.1,2 Originally
thought to be dentin-specific, the expression
of DSPP has also been detected in bone,3
cementum,4 cartilage,5 and some non-mineral-
ized tissues5,6 at a lower level. The importance
of DSPP in biomineralization has been evi-
denced by human and mouse genetic studies,
which showed the association of DSPP gene
mutations or ablations with the mineralization
defects in dentin7-10 and bone.11 However, the
exact mechanism by which DSPP functions in
skeletal and dental development remains
largely unclear.
As a large precursor protein, DSPP is
cleaved by proteases to form three major com-
ponents:12-14 an NH2-terminal fragment known
as dentin sialoprotein (DSP), a proteoglycan
form of the NH2-terminal fragment referred to
as DSP-PG, and a COOH-terminal fragment
named dentin phosphoprotein (DPP).15-17 The
DSP/DSP-PG-coding sequence is on the 5’ side,
and the DPP is on the 3’ side of the DSPP tran-
script. DSP and DPP were independently iden-
tified as extracellular matrix (ECM) compo-
nents extracted from dentin and were discov-
ered much earlier than DSPP. DPP was discov-
ered in 196718 and is the most abundant NCP
in the dentin matrix. It is an unusually polyan-
ionic protein, containing a large number of
aspartic acids (Asp) and phosphoserines (Pse)
in the repeating sequences of (Asp-Pse)n. and
(Asp-Pse-Pse)n .19,20 A very different protein,
DSP, was discovered in 1981;21 it is a sialic
acid-rich glycoprotein, with little or no phos-
phate. The DSP-PG component has been
reported by both our group and others.16,17 DSP-
PG is present in the dentin extracellular
matrix (ECM) in significant amounts, suggest-
ing that DSP-PG may be the functional form of
DSPP NH2-terminal fragment.22
The remarkable difference in chemical
structures between the NH2-terminal fragment
(DSP/DSP-PG) and the COOH-terminal frag-
ment (DPP) of DSPP suggests that these vari-
ous fragments may perform different functions
in biomineralization23 although they are
encoded by the same mRNA. Studies have
shown that significant amounts of DSP/DSP-
PG and DPP are present in the ECM of dentin,
whereas only trace amounts of the full-length
form of DSPP is detectable in the dentin.24 A
recent study in our laboratory has shown that
blocking the proteolytic processing of DSPP
leads to hypomineralization defects in dentin,
similar to those observed in Dspp-deficient
subjects.25 This observation strongly indicates
that the proteolytic processing of DSPP into
different fragments is an essential activation
step in dentinogenesis. Several in vitro miner-
alization studies have indicated that DPP is
involved in nucleation and modulation during
the formation and growth of hydroxyapatite
crystals.26-28 The highly negatively charged DPP
is thought to play a role in promoting mineral-
ization by binding and presenting calcium ions
to collagen fibers at the mineralization
front.29,30 DSP does not have a significant effect
on the apatite formation and growth in vitro.31
In vivo studies involving the transgenic
expression of DSPP NH2-terminal fragments in
the Dspp-knockout (KO) background indicated
that these fragments may regulate the initia-
tion of dentin mineralization, whereas DPP
controls the maturation of dentin mineraliza-
tion.32 However, the precise biological mecha-
nisms of these fragments in mineralization
have not yet been elucidated.
To examine the in vivo function of DSPP
fragments in biomineralization, we first gener-
ated transgenic mice overexpressing DSPP
NH2-terminal fragments and found that the
transgenic expression of DSPP NH2-terminal
fragments  worsened the dentin defects of the
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Dspp null mice.33 In this study, we generated
transgenic mice overexpressing the hemagglu-
tinin (HA)-tagged DPP under the control of a
3.6 kb type I collagen (Col1a1) promoter
(referred to as Col1a1-HA-DPP) in the
C57BL/6J wild type (WT) mouse genetic back-
ground. We analyzed the skeletal phenotype of
the Col1a1-HA-DPP transgenic mice and found
that these transgenic mice had a smaller body
size and shorter long bone, reduced trabecular
bone formation and reduced cell proliferation
in the proliferating zone of growth plates com-
pared with their WT littermates. Our findings
suggest that overexpression of DPP suppress-
es skeletal development. 
Materials and MethodsGeneration of HA-DPP expressionconstruct
DPP is the C-terminal fragment of DSPP,
generated by the proteolytic cleavage of the
full-length DSPP in the secretory pathway, so
DPP does not have its own endoplasmic reticu-
lum (ER)-entry signal peptide (SP). In addi-
tion, DPP does not have its own ER-exit signal
peptide, as the first three amino acid residues
(isoleucine-proline-valine or IPV) after the ER-
entry signal peptide cleavage site are required
for the efficient export of DSPP from ER to the
Golgi complex in the secretory pathway.10
Therefore, to ensure the proper secretion of
DPP, we generated a cDNA (referred to as HA-
DPP) that encoded a protein in which the
mouse DPP (containing 494 amino acid
residues) was fused to the first 25 amino acids
of DSPP (including the 17 amino acid residues
of the ER-entry signal peptide and the first
eight amino acid residues of mature DSPP)
(Figure 1A). In addition, a hemagglutinin (HA)
tag was inserted at the amino-terminal end of
DPP to allow detection of the transgenic DPP
protein. Since specific antibodies against DPP
are not available, tagging the HA epitope to
DPP allows us to employ anti-HA antibodies to
detect DPP in the cell lines and the transgenic
animals. The HA-DPP cDNA was generated by
a combination of DNA synthesis and poly-
merase chain reaction (PCR), and cloned
downstream of a cytomegalovirus (CMV) pro-
moter in pCDNA3 expression vector
(Invitrogen, Grand Island, NY, USA). The HA-
DPP cDNA was confirmed by DNA sequencing. Generation of transgenic miceexpressing HA-DPP
We previously generated transgenic mice
expressing normal DSPP under the control of a
3.6/1.6 kb Col1a1 promoter/intron fragment
and demonstrated that normal DSPP fully res-
cued the dentin defects of Dspp-null mice.25 To
determine the in vivo function of DPP, we gen-
erated transgenic mice expressing HA-DPP
under the control of the same 3.6/1.6 kb Col1a1
promoter/intron fragment (referred to as
Col1a1-HA-DPP). Briefly, the HA-DPP coding
sequence was cloned downstream of the
3.6/1.6 kb Col1a1 promoter/intron fragment fol-
lowed by the SV40 polyadenylation signal in
the pBC-KS vector. The Col1a1-HA-DPP trans-
gene was released by SacII and SalI restriction
endonucleases, separated from the vector
backbone by agarose gel electrophoresis, and
purified using Elutip-D columns (Whatman
Schleicher & Schuell Bioscience, Inc., Keene,
NH, USA). The transgenic mice were generat-
ed on a C57BL/6J genetic background by
pronuclear injection at the Transgenic
Technology Center of the University of Texas
Southwestern Medical Center, Dallas, TX, USA.
Founder mice were identified by PCR analysis
of genomic DNA extracted from tail biopsies
using the following two sets of primers specific
for the transgene: set 1, forward primer, 5-
GATGGTGACAGCAAGTCTGG-3’, located on the
Col1a1 intron fragment; and reverse primer, 5 -
TGTCCAAACTCATCAATGTATCT-3’, located on
the HA-DPP coding sequence. Set 2, forward
primer, 5’-TGGTGGTGCAAATCAAAGAA-3’,
located on DPP coding sequence, and reverse
primer, 5’-CTGTCACTGTCACCATCACCATTAC-
3’, located on SV40 polyadenylation signal. The
size of the PCR product was ~200 bp for the
first set of primers, and ~500 bp for the second
set of primers.
Both female and male transgenic mice were
included in the experiments since there was
no apparent phenotypic difference between
genders. The age- and sex-matched WT litter-
mates were used as control mice. All animal
protocols were approved by the Animal Welfare
Committee of the Texas A&M University
Baylor College of Dentistry. Cell culture and transfection
Human embryonic kidney cells (HEK-293
EBNA) were cultured as described previously.34
Briefly, HEK-293 EBNA cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum
(Invitrogen). For transfection, HEK-293 EBNA
cells were transiently transfected with a con-
struct expressing HA-DPP or pCDNA3 empty
vector with X-tremeGENE 9 DNA transfection
reagent (Roche, Indianapolis, IN, USA),
according to the manufacturer’s instructions.
The transfection medium was replaced with
serum-free medium 16-18 h after transfection
and then the transfected cells were cultured
for an additional 48 h. The conditional medium
was collected and analyzed for HA-DPP-related
proteins by Western immunoblotting with an
anti-HA monoclonal antibody (Covance Inc.,
Dallas, TX, USA) at a dilution of 1:1000.
RT-PCR and qRT-PCR
Total RNAs were extracted from the long
bones of 4-week-old Col1a1-HA-DPP trans-
genic mice and WT mice using an RNeasy mini
kit (QIAGEN, Germantown, MD, USA). The
RNAs (1 µg per sample) were then reverse-
transcribed into cDNAs using the QuantiTect
Reverse Transcription Kit (QIAGEN). RT-PCR
was performed to examine the expression of
the exogenous DPP transgene in bone. The
primers used for RT-PCR were: forward, 5 -
GATGGTGACAGCAAGTCTGG-3’ (in the C-ter-
minal region of DPP) and reverse, 3 -TGTC-
CAAACTCATCAATGTATCT (in SV40 poly A tail).
The housekeeping gene, glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) was used
as the internal control. The reaction condition
was: 95°C for 4 min, 60°C for 30 s and 72°C for
30 s, 35 cycles. Real time RT-PCR was per-
formed using Go Tag® qPCR Master Mix
System (Promega, Madison, WI, USA) and
CFX96 Real-Time PCR Detection System (Bio-
Rad, Hercules, CA). The qRT-PCR condition
was: initial denaturation at 95°C for 2 min, fol-
lowed by 40 cycles of 95°C for 30 s, 60°C for 1
min. The DPP primers for qRT-PCR were
designed to amplify both endogenous DSPP
and transgenic DPP transcripts, and they were:
forward primer, 5 - CAGCAAGGATAGCAGTTCT-
GA-3 ; and reverse primer, 5 -TGTCACTGC-
CTTCACTGTCAC-3 . The housekeeping gene,
Gapdh, was used as the internal control. The
primers for Gapdh were: forward primer, 5’-
GAAGCCCATCACCATCTTC-3’; and reverse
primer, 5’- GTTCACACCCATCACAAACA-3’. The
data were analyzed using the 2- CT Method, The
mRNA level in the WT mice was set as one, and
the mRNA levels of transgenic mice were cal-
culated relative to that in the WT mice.Extraction of NCPs and detectionof HA-DPP-related proteins
Non-collagenous proteins (NCPs) were
extracted from long bones of 4-week-old DPP
transgenic and WT mice using a protocol
described previously.24 Equal amounts of sam-
ples were loaded onto 4-12% SDS-PAGE gel.
Western immunoblotting was performed to
identify the HA-DPP-related proteins in the
long bone and incisor extracts, using an anti-
HA monoclonal antibody (Covance Inc.) at a
dilution of 1:1000. The blots were incubated in
HRP-conjugated goat anti-mouse IgG second-
ary antibody (Santa Cruz, Dallas, TX) at a dilu-
tion of 1:5000, followed by incubation in a
chemiluminescent substrate for 3 min and
subsequent exposure to X-ray films. Plain X-ray radiography and high-resolution microcomputed tomog-raphy (μCT)
Both the Col1a1-HA-DPP transgenic mice
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and WT mice or long bones dissected from
these mice at the ages of 3 and 12 weeks were
analyzed using a Faxitron MX-20 Specimen
Radiography System with a digital camera
attached (Faxitron X-ray Corp., Buffalo Grove,
IL, USA). The femurs from 3-week-old mice
were further scanned using a Scanco μCT35
imaging system (μCT35, Scanco Medical,
Bassersdorf, Switzerland) with a slice incre-
ment of 7 μm at medium resolution to assess
the overall shape and structure. The three-
dimensional (3-D) structure was constructed
at the threshold of 150. Following this evalua-
tion, a high-resolution scan in 3.5 μm slice
increments was performed to examine the
midshaft cortical bone parameters and the dis-
tal metaphyseal trabecular bone microarchi-
tecture of the femurs. The morphometric
parameters analysis was performed using the
built-in software of theμCT system. The corti-
cal bone volume fraction (bone volume/total
volume, %) and material density were obtained
from 231 slices at the mid-shaft of the femurs
at a threshold of 283. The trabecular bone vol-
ume fraction and material density were meas-
ured on a set of 200 sections underneath the
growth plate at a threshold of 250. The various
thresholds used to segment bone from soft tis-
sues were specimen-specific. Each threshold
was chosen based on visual comparisons
between slice-wise 2D unsegmented and seg-
mented images, and a fixed threshold was
applied for the same sample type. The data
acquired from the high-resolution scans of
four samples per group were used for the
quantitative analysis.Histology analysis
For histologic analysis, the bone samples
were fixed in freshly prepared 4%
paraformaldehyde in phosphate-buffered
saline (pH 7.4) at 4°C overnight and then
decalcified in 15% ethylenediamine -
tetraacetate (EDTA) solution (pH 7.4) at 4°C
for 5~14 days depending on the ages of the
animals. The samples were embedded in paraf-
fin using standard histological procedures.
The tissue blocks were cut into 5-µm thick
serial sections and were then used for
Hematoxylin and Eosin (H&E) staining,
Safranin O staining, toluidine blue staining or
immunohistochemistry (IHC). For IHC analy-
ses, monoclonal anti-HA antibody (1:2000) was
used to recognize the HA epitope tagged to
DPP protein. The IHC experiments were car-
ried out using the M.O.M. kit and the DAB kit
(Vector Laboratories, Burlingame, CA, USA,
USA) according to the manufacturer’s instruc-
tions. For BrdU analysis, the animals at 3-week
of age were injected with BrdU (5-Bromo-2’-
deoxyuridine, 100 µg/g mouse, i.p.; Sigma-
Aldrich, St. Louis, MO, USA) twice (the first
injection was 24 hours and the second was 2
hours before sacrifice). The long bones were
collected and processed for paraffin sectioning
as described above. The BrdU-labeled cells
were detected using a BrdU staining kit
(Invitrogen) according to the manufacturer’s
instruction. To quantify cell proliferation,
images of the growth plate areas were cap-
tured under a 20x objective, BrdU-positive
nuclei and total nuclei in the zone of prolifera-
tive chondrocytes were counted. The percent-
ages of BrdU-labeled cells among the total pro-
liferative chondrocytes were calculated as a
measure of cell proliferation. 
In situ hybridization was carried out to
assess the expression of type II collagen (Col
II) and type X collagen (Col X) in 10-day-old
long bone samples from the Col1a1-HA-DPP
transgenic mice and their WT littermates as
described previously.35 Briefly, the RNA probes
were labeled with digoxigenin (DIG) using a
RNA Labeling Kit (Roche) according to the
                             Original Paper
Figure 1. Generation of HA-DPP expression construct. A) The HA-DPP expression construct was  designed to encode a protein that
included the 17 amino acid residues of mouse DSPP ER entry signal peptide, the first eight amino acid residues of mature DSPP
(including the IPV motif ) and the 494 amino acid residues of mouse DPP; an HA tag was inserted at the NH2-terminal end of DPP
as indicated. B) Expression of HA-DPP in HEK-293 EBNA cells; Western immunoblotting was performed with anti-HA antibody to
detect the secreted HA-DPP protein in the conditioned medium collected from the cells transfected with pCDNA3-HA-DPP expression
construct. C) Genotyping strategy; the transgenic (Tg) mice were genotyped by PCR using 2 different sets of primes specific for the
transgene, giving rise to a ~200 bp fragment and ~500 bp fragment, respectively. 
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manufacturer’s instruction. DIG-labeled RNA
probes were detected by an enzyme-linked
immunoassay with a specific anti-DIG-alkaline
phosphatase antibody conjugate (Roche) and a
VECTOR red alkaline phosphatase substrate
(Vector Laboratories, Burlingame, CA, USA),
which produced a red color for positive signals.
The sections were counterstained with methyl
green.
Alcian blue/alizarin red staining ofthe skeleton
Alcian blue/alizarin red staining was per-
formed to analyze the overall skeletal and min-
eralization defects as described previously.36
Briefly, 16-day-old Col1a1-HA-DPP transgenic
mice and control mice were sacrificed,
skinned, eviscerated and fixed for three days
in 95% ethanol. They were then stained with
alcian blue for cartilage and alizarin red for
bone. Statistical analysis
The data were expressed in terms of mean ±
SD (standard deviation). Two-group data were
analyzed with an unpaired Student’s t-test.
P≤0.05 was considered as the statistically sig-
nificant difference for all comparisons. 
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Figure 2. Expression of HA-DPP in the long bones of Col1a1-HA-DPP transgenic mice. A)  RT-PCR was performed to specifically
detect transgenic DPP transcripts using total RNAs extracted from the long bones of 4-week-old transgenic (Tg) and wild type (WT)
mice; lines 1, 2 and 3 showed a strong expression band. B) Real time PCR analysis showed the relative expression level of DPP mRNA
in six Tg lines (line1-6); the mRNA expression in WT samples was set as 1 and the fold changes in the six Tg lines were calculated rel-
ative to that of the WT mice; the line 1 mice showed the highest mRNA level (approximately 7-fold higher than that of the endogenous
gene expression in the WT mice). C) Western immunoblotting analyses was carried out with an anti-HA antibody to detect transgenic
HA-DPP protein in the 4-week-old long bone extracts of WT , line 2 and line 1 Tg mice; HA-DPP protein was detected in the line 1
and line 2, but not in the WT mice. D) Immunohistochemical staining of HA-DPP in the tibiae of 3-week-old mice.  Note the strong
HA-DPP protein signals in the line 1 Tg mice, compared to those in the line 2 Tg mice; scale bars: 200 µm. E) Higher magnification
image showed that the HA-DPP protein was mainly found in the long bone matrix. BM, bone marrow, CT, cortex; scale bars: 20 µm.
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ResultsGeneration of Col1a1-HA-DPPtransgenic mice
To confirm the expression and secretion of
HA-DPP, the HA-DPP-expressing construct was
transiently transfected into HEK-293 EBNA
cells. Western-blotting analysis with the anti-
HA antibody showed that HA-DPP protein was
readily detected in the conditioned medium
harvested from the cells transfected with HA-
DPP-expressing construct (Figure 1B), sug-
gesting the successful expression and secre-
tion of the HA-DPP protein. 
The Col1a1-HA-DPP transgenic mice were
then generated to determine the in vivo func-
tion of DPP. The founder mice were identified
by PCR analysis of tail genomic DNA (Figure
1C). A total of fifteen Col1a1-HA-DPP founders
were obtained and bred with C57BL/6J wild
type mice to establish transgenic lines for fur-
ther analysis. To our surprise, six founders
died within 6 months without any obvious
gross defects; one founder failed to produce
any pups; and two founders failed to pass the
transgene on to their offspring. Therefore, only
6 founders produced F1 transgenic mice and
were analyzed in this study.Expression of Col1a1-HA-DPPtransgene in bone
The transgenic expression of HA-DPP in
bone was first confirmed at the transcript level
by RT-PCR and qRT-PCR, using total RNAs
extracted from the long bones of the six
Col1a1-HA-DPP transgenic lines (Figure 2
A,B). The RT-PCR primers were designed
specifically to detect the transgenic DPP tran-
scripts, but not the endogenous DSPP tran-
scripts. As shown in Figure 2A, the lines 1, 2
and 3 showed a strong DPP expression band,
whereas the lines 4, 5 and 6 had very weak
bands (Figure 2A). The relative expression
level of the DPP transgene in the long bones
from the six lines of transgenic mice was
determined using qRT-PCR analyses with
primers that amplified both transgenic DPP
transcripts and endogenous DSPP transcripts
(Figure 2B). Consistent with RT-PCR results,
the lines 1, 2 and 3 had higher levels of trans-
gene expression compared to the wild type
mice. In contrast, the lines 4, 5 and 6 showed
extremely low levels of transgene expression,
suggesting that the transgene was barely
active in the lines 4, 5 and 6. 
The transgene expression in the line 1 and
line 2 mice was further confirmed at the pro-
tein level by WB and IHC analyses using the
anti-HA monoclonal antibody. The line 3 was
not analyzed because we failed to obtain any
more transgenic progenies from the founder 3.
Western immunoblotting analysis was per-
formed on NCP extracted from the long bones
of the lines 1 and 2 and WT mice. As shown in
Figure  2C, HA-DPP related proteins were
detected in both lines 1 and 2 samples but not
in the WT sample. IHC analysis showed that
the HA-DPP protein signals were mainly local-
ized in the matrices of the long bones in both
lines 1 and 2 mice (Figure  2 D,E). Both WB
and IHC analyses revealed a higher level of HA-
DPP related proteins in the line 1 transgenic
mice, compared with the line 2 mice.Skeletal defects associated with thetransgenic expression of DPP
Having confirmed the transgene expression
in the lines 1 and 2, we next analyzed the
skeletal phenotype of these two transgenic
lines. The line 2 transgenic mice were smaller
compared with their WT littermates as demon-
strated by plain X-ray radiography at 4 wks of
age (Figure 3A) and body weight monitoring
from postnatal 3 weeks to postnatal 9 weeks
(Figure 3B). Plain X-ray radiography showed
that the radiopacity of the femurs/tibiae from
3- and 12-wk-old line 2 mice appeared to be
similar as those from the WT littermates
(Figure 3C). The µCT images demonstrated
that the femurs from 3-wk-old line 2 mice were
shorter and had reduced trabecular bone in the
distal metaphysis area, compared with those
from the WT femurs (Figure  3D). The quanti-
tative µCT analysis confirmed that the femurs
of the line 2 transgenic mice were significantly
shorter than the WT mice (Table 1). In addi-
tion, the distal growth plate thickness of femur
in the line 2 mice showed a significant 50%
reduction compared to that in the WT control
mice (Table 1).  Although the ratio of BV/TV
was slightly increased in the cortical bone, it
was significantly reduced in the trabecular
bone in the line 2 transgenic mice (Table 1).
However, there was no significant difference
in other bone parameters, including the corti-
cal and trabecular bone mineral density as well
as the trabecular bone number, thickness and
separation between the line 2 and WT mice
(Table 1). Furthermore, we also analyzed sev-
eral bone matrix proteins, including bone
sialoprotein (BSP), osteopontin (OPN), bigly-
can and dentin matrix protein 1 (DMP1), by
immunohistochemistry and did not find appar-
ent difference between the line 2 transgenic
and WT mice (data not shown).
Consistent with the high level of transgene
expression, the line 1 transgenic mice had
much severe skeletal defects. In fact, we never
obtained any F2 transgenic mice from this
line, which was most likely because the F1
mice had prominent dwarfism and severe long
bone defects. Plain x-ray radiography showed
that the line 1 transgenic mice were remark-
ably smaller than their WT littermates at 4 wks
of age (Figure 3A). Some line 1 mice developed
spontaneous long bone fracture (Figure 3C).
Few of the line 1 transgenic mice (F1) could
survive to the adult age, but X-ray radiography
showed that they had poorly formed long bones
(Figure 3C). Alizarin red/alcian blue staining
of the skeletons of 16-day-old mice also
showed that the line 1 transgenic mice had
much smaller skeletons (Figure 4A), abnormal
elbow joint in the forelimb (most likely due to
a previous bone fracture in the ulna near the
                             Original Paper
Table 1. Quantitative µCT analysis of femur midshaft cortical bone and distal metaphysis trabecular bone.
                                                                                                   WT                                                                   Line 2
Femur length (mm)                                                                                  10.070±0.286                                                                             8.354±0.559**
Distal growth plate thickness (mm)                                                       0.218±0.027                                                                             0.101±0.010***
Midshaft cortical bone parameters                                                                  
BV/TV                                                                                                       0.163±0.018                                                                             0.204±0.030
Bone mineral density (mg HA/cm3)                                             776.138±26.343                                                                      763.159±18.258
Trabecular bone parameters                                                                                                                                                                                
Tb.N. (mm-1)                                                                                          2.602±0.084                                                                             2.365±0.178
Tb.Th (mm)                                                                                           0.024±0.003                                                                             0.022±0.001
Tb.Sp (mm)                                                                                           0.392±0.015                                                                             0.426±0.033
BV/TV                                                                                                       0.020±0.006                                                                             0.011±0.003*
Bone mineral density (mg HA/cm3)                                             630.761±19.946                                                                      647.288±19.213
BV, bone volume; TV, total (tissue) volume; Tb.N., trabecular bone number; Tb.Th, trabecular bone thickness; Tb.Sp, trabecular bone separation. Values are expressed as mean ±SD from four 3-week-
old mice per group. *P<0.05; **P<0.01; ***P<0.001.
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Figure 3. Skeletal defects of Col1a1-HA-DPP  transgenic mice. A) Plain X-ray radiographs of 3-week-old Tg mice showed that both the line
2 and line 1 mice were smaller, compared with the WT littermates; scale bars: 5 mm. B) Body weight monitoring of the male line 2 Tg mice
and WT littermates from postnatal 3 weeks to postnatal 9 weeks; note that the line 2 Tg mice showed significantly lower body weight com-
pared to the WT littermates, starting from 5-wk of age; *P<0.05,  n=4. C) Plain X-ray radiographs of the hind limbs  at different ages; the
femurs and tibiae of both the line 2 and line 1 Tg mice were shorter than their WT littermates; the femur of the line 1 Tg mice developed
spontaneous fracture (asterisk) at 3-wk of age; scale bars: 1 mm. D) Representative µCT images of the entire femurs (upper left panel), the
coronal sections of the femurs (upper right panel), the femoral midshaft (lower left panel) and the femoral distal metaphysis (lower right
panel) from 3-week-old line 2 Tg mice and their WT littermates; upper scale panel bars: 1 mm; lower panel scale bars: 500 µm.
Figure 4. Alcian blue and alizarin red staining of the skeletons of 16-day-old  WT and line 1 Tg mice. The Tg mice had much smaller
skeletons, compared with WT littermates (A), and showed abnormal elbow joints (arrow) in the forelimb (B), underdeveloped epiphysis
in both femur and tibia (C) and less cartilage (less blue staining) in the growth plate area (C,D). Scale bars: A) 10 mm; B-D) 1 mm.
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elbow joint) (Figure 4B), shorter femurs, tibia
(Figure 4C), shorter phalanges (Figure 4B)
and less cartilage in the growth plate area
(Figure  4 C,D). 
Collectively, these results demonstrated that
the transgenic expression of DPP inhibited
long bone growth and endochondral bone for-
mation and that such effect became more
severe as the level of transgene expression
increased. 
Transgenic expression of DPP ledto reduced cell proliferation in thegrowth plate
Next, we determined whether the short
bone length observed in the Col1a1-HA-DPP
transgenic mice was due to the defects in the
growth plate. Consistent with µCT analysis, HE
staining of the sagittal sections of the tibia
showed that both lines 1 and 2 transgenic mice
displayed narrower zones of proliferative and
hypertropic chondrocytes at 3 wks of age
(Figure  5A). However, as the epiphysis and
metaphysis begin to fuse at 12 wks of age, the
width of the growth plates of the transgenic
and WT mice did not appear to be different
(Figure 5B). Therefore, we examined whether
there was a defect in cell proliferation in the
growth plates of the line 2 transgenic mice, as
we could not obtain more samples from the
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Figure 5. Growth plate defects of Col1a1-HA-DPP transgenic mice. HE staining of the sagittal sections of tibia growth plate areas at
3-wk of age (A) and 12-wk-of age (B). At 3-wk of age, both line 1 and line 2 mice showed a narrower zone of hypertropic chondrocytes
and narrower zone of proliferative chondrocytes compared to the WT mice. At 12-wk of age, the width of the growth plate did not
show obvious difference between the Tg and WT mice. Scale bars: 100 µm.
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Figure 6. Cell proliferation in the growth plates of the line 2 transgenic mice. A) BrdU immunostaining revealed that the BrdU-positive
cells (signal in brown) were fewer in the proliferative zone of the growth plates in the line 2 Tg mice than those in the WT mice. B)
The quantified data showed that BrdU labeling cells in the proliferative zone of the growth plates significantly decreased in the line 2
Tg mice, compared to those in the WT mice. The data were expressed as the percentage of BrdU-positive nuclei versus total proliferative
chondrocytes. **P<0.01, n=5. Scale bars: 100 µm.
line 1 founder. As shown in Figure 6, the ratio
of BrdU-positive cells to the total number of
cells in the proliferative zone of the growth
plate was significantly reduced in the line 2
transgenic mice compared to that in the WT lit-
termates, suggesting a reduced cell prolifera-
tion as a result of transgenic expression of HA-
DPP. We then determined whether there was a
defect in the chondrocyte differentiation in the
growth plate. We analyzed the expression of
chondrocyte differentiation markers, including
type II collagen (Col II, a marker for the prolif-
erating chondrocytes) and type X collagen (Col
X, a marker for the hypertrophic chondrocytes)
in the growth plates of 10-day-old line 2 trans-
genic mice and their WT littermates by in situ
hybridization analyses. As shown in Figure 7A-
B, the signal intensities of both Col II and Col
X mRNA in the line 2 transgenic mice were
comparable to those in the WT mice. In addi-
tion, we analyzed the proteoglycan expression
in the growth plate of 3-wk-old line 2 trans-
genic mice and their WT littermates by both
safranin O and toluidine blue stainings.
Safranin O stains cartilage red while toluidine
blue stains cartilage blue. As shown in Figure
7 C-D, although both stainings revealed a nar-
rower growth plate in the line 2 transgenic
mice, the staining intensities appeared to be
similar in the line 2 transgenic mice and the
WT mice. Taken together, these findings sug-
gested that the growth plate defects in the
Col1a1-HA-DPP transgenic mice were mainly
due to the reduced cell proliferation, but was
not due to a defect in the chondrocyte differen-
tiation.
Discussion
In the ECM of dentin and bone, DSPP is
mainly present as the processed DSP, DSP-PG
and DPP. DPP is very unique because it is a
highly phosphorylated and acidic protein. To
determine the function of DPP in vivo, we gen-
erated Col1a1-HA-DPP transgenic mice
expressing DPP in the osteoblast/osteocyte lin-
eage under the control of a 3.6 kb type I colla-
gen promoter. These transgenic mice had a
smaller body size, shorter long bones and
decreased bone formation. Furthermore, we
found that these skeletal defects became more
severe as the level of the Col1a1-HA-DPP
transgene expression increased. 
The Col1a1-HA-DPP transgenic mice are a
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useful animal model to study the function of
DPP in vivo. Due to the special chemical fea-
ture of DPP, it is a challenge to generate spe-
cific anti-DPP antibodies. In these transgenic
mice, an HA-tag was inserted at the amino-ter-
minus of DPP to allow the detection of the
transgenic DPP protein with an anti-HA anti-
body. IHC analyses with the monoclonal anti-
HA antibody showed that the DPP protein was
found in the ECM of the long bones, suggest-
ing that the DPP protein was properly secreted
in vivo. The predicted molecular weight for
mouse DPP is about 50 kDa. However, the
actual size of mouse DPP was not known, due
to lack of specific anti-DPP antibody. By taking
advantage of HA tag, we detected a smear of
HA-DPP protein with an observed size ranging
from 90 to 200 kDa in both conditioned medi-
um harvested from HEK-293 EBNA cells trans-
fected with HA-DPP-expressing construct and
bone extracts of Col1a1-HA-DPP transgenic
mice. These observations suggest that HA-DPP
has undergone extensive posttranslational
modifications in both HEK-293 EBNA cells and
osteoblasts. Therefore, this specific transgenic
model provides a novel tool to study the subcel-
lular and extracellular localization of DPP and
to monitor the posttranslational modification
of DPP in vivo.
DPP is a highly phosphorylated and acidic
molecule. While a number of studies have sug-
gested that it plays an important role in bio-
mineralization through initiating hydroxyap-
atite crystal nucleation and modulating crystal
growth, most of these studies were performed
in an in vitro cell-free system.27,28,37-40 In this
study, we showed that overexpression of DPP
in the osteoblast/osteocyte lineage resulted in
reduced bone formation and spontaneous bone
fractures. As the spontaneous bone fractures
were only observed in the line 1 transgenic
mice, but not in the line 2 transgenic mice,
these bone fractures were most likely associat-
ed with the much thinner bones formed in the
line 1 transgenic mice. Our current findings
suggest that excessive DPP may suppress bio-
mineralization and also indicate that the in
vivo biomineralization is a rather complicated
process. 
In addition, we also showed that the Col1a1-
HA-DPP transgenic mice displayed small skele-
ton and shorter bone length. The shorter bone
length was apparently due to the reduced cell
proliferation in the proliferating zone of the
growth plates, but not due to a defect in the
chondrocyte differentiation. Fibroblast growth
factor 3 (Fgfr3) plays essential roles in regulat-
ing longitudinal bone growth through sup-
pressing both proliferation and differentiation
of the growth plate chondrocytes.41 Accordingly,
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Figure 7. Chondrocyte differentiation in the growth plates of the line 2 transgenic mice. In situ hybridization (ISH) staining of Col II
(A) and Col X (B) on the sagittal sections of tibia growth plate indicated that there was no apparent difference in signal intensities
(pink/red color) for both Col II and Col X mRNAs between the 10-day-old line 2 transgenic mice and the WT mice. Safranin O (C)
and Toluidine Blue (D) stainings of the sagittal sections of the tibia growth plates from 3-week-old mice. Both stainings showed a nar-
rower zone of cartilage in the growth plate in the Tg mice compared to that in the WT mice, but the staining intensity appeared to be
similar between the Tg and WT mice. Scale bars: A,B) 20 µm; C,D) 100 µm.
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gain of function mutations in FGFR2 gene
results in achondroplasia (ACH) or much more
severe and lethal form of dwarfism known as
thanatophoric dysplasia (TD) in humans.42-45
Therefore, we determined the level of Fgfr3
expression in the growth plate chondrocytes by
immunohistochemistry. No apparent differ-
ence was observed in Fgfr2 expression in the
line 2 transgenic mice and wild-type mice
(data not shown). This was consistent with
our other findings, showing that only prolifer-
ation of growth plate chondrocytes were affect-
ed, but growth plate chondrocyte differentia-
tion appeared to be normal in the line 2 trans-
genic mice. These observations suggest that
the growth plate defects are unlikely caused by
elevated Fgfr3 signaling. How transgenic
expression of HA-DPP causes the growth plate
defects remains to be further studied.
Although the Col1a1-HA-DPP transgene was
mainly active in the osteoblast/osteocyte line-
age, a low level of HA-DPP might also be
expressed in the growth plate chondrocytes,
but was not readily detected by immunohisto-
chemistry. Such a low level of HA-DPP may
account for the growth plate defects observed
in the HA-DPP transgenic mice. 
In contrast to DPP, overexpression of DSP in
the wild type mouse genetic background did
not lead to apparent skeletal defects, but it
worsened the dentin and periodontal defects of
the Dspp null mice.33 46 While overexpression of
the full-length DSPP did not cause any obvious
skeletal defects in the wild type mouse genetic
background, it rescued the dentin defects of
Dspp null mice.25 Furthermore, the failure to
process DSPP into DSP and DPP blocked the
normal function of DSPP, and failed to rescue
the dentin defects of Dspp null mice.25
Altogether, these findings not only suggest that
the proteolytic processing of DSPP into DSP
and DPP is essential for the normal function of
DSPP, but also imply that both DSP and DPP
are required for the normal function of DSPP
in the skeletal and dental development.   
In conclusion, we generated transgenic
mice overexpressing DPP in the
osteoblast/osteocyte lineage and showed that
overexpression of DPP inhibited skeletal
development.
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